RECRUITING

Thalamus Seizure Detection With a Deep Brain Stimulator System

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to determine the feasibility of chronic ambulatory thalamus seizure detection. The sensitivity, specificity, and false alarm rate of thalamus seizure detection will be calculated using recordings from a deep brain stimulation system, assessed relative to concurrent gold-standard video-EEG monitoring collected in the in-patient setting (epilepsy monitoring unit), in 5 patients with drug resistant epilepsy.

Official Title

Seizure Detection With a Deep Brain Stimulation System

Quick Facts

Study Start:2025-09-01
Study Completion:2027-05
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06700356

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * 18 years of age and older.
  2. * Implanted with a clinical DBS system for epilepsy with brain recording capabilities (Medtronic Percept™ DBS).
  3. * Subject or legally authorized representative is able to understand study procedures and to comply with them for the entire length of the study.
  1. * Health status or any clinical conditions (e.g., life expectancy, co-existing disease) that, in the opinion of the site investigator, would pose undue risk to undergo epilepsy monitoring unit evaluation for the purpose of seizure characterization.
  2. * Women will verify not pregnant, and if applicable, have urine pregnancy test.
  3. * Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
  4. * Inability or unwillingness of individual or legal guardian/representative to give written informed consent.

Contacts and Locations

Study Contact

Karla Crockett
CONTACT
507-538-4880
crockett.karla@mayo.edu

Principal Investigator

Nicholas Gregg
PRINCIPAL_INVESTIGATOR
Mayo Clinic

Study Locations (Sites)

Mayo Clinic in Rochester
Rochester, Minnesota, 55905
United States

Collaborators and Investigators

Sponsor: Mayo Clinic

  • Nicholas Gregg, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-09-01
Study Completion Date2027-05

Study Record Updates

Study Start Date2025-09-01
Study Completion Date2027-05

Terms related to this study

Additional Relevant MeSH Terms

  • Epilepsy; Seizure